A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases

Objectives Our aim was to assess the value of nintedanib for non-idiopathic progressive fibrosing interstitial lung disease (non-IPF PF-ILD) and systemic sclerosis-associated ILD (SSc-ILD) in the Spanish context, using a multi-criteria decision analysis (MCDA). Methods Following an adaptation of the...

Full description

Bibliographic Details
Authors: Zozaya, Néboa|||0000-0003-4618-6894, Arrizubieta Basterrechea, M.I., Bollo, Elena, Castellvi, Ivan|||0000-0002-5410-5807, Espín, Jaime, Ortego, Norberto, Poveda-Andrés, José Luis, Rodríguez Portal, José Antonio, Rivero, Agustín, Marcos-Rodríguez, José Antonio, Verde, Luis
Format: article
Publication Date:2022
Country:España
Institution:Universitat Autònoma de Barcelona
Repository:Dipòsit Digital de Documents de la UAB
Language:English
OAI Identifier:oai:ddd.uab.cat:290599
Online Access:https://ddd.uab.cat/record/290599
https://dx.doi.org/urn:doi:10.1017/S0266462322000459
Access Level:Open access
Keyword:Interstitial lung diseases
Multi-criteria decision analysis
Pulmonary fibrosis
Systemic sclerosis
id ES_c76792b22a4efe80dee2bcdd2474a5c8
oai_identifier_str oai:ddd.uab.cat:290599
network_acronym_str ES
network_name_str España
repository_id_str
spelling A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseasesZozaya, Néboa|||0000-0003-4618-6894Arrizubieta Basterrechea, M.I.Bollo, ElenaCastellvi, Ivan|||0000-0002-5410-5807Espín, JaimeOrtego, NorbertoPoveda-Andrés, José LuisRodríguez Portal, José AntonioRivero, AgustínMarcos-Rodríguez, José AntonioVerde, LuisInterstitial lung diseasesMulti-criteria decision analysisPulmonary fibrosisSystemic sclerosisObjectives Our aim was to assess the value of nintedanib for non-idiopathic progressive fibrosing interstitial lung disease (non-IPF PF-ILD) and systemic sclerosis-associated ILD (SSc-ILD) in the Spanish context, using a multi-criteria decision analysis (MCDA). Methods Following an adaptation of the Evidence and Value: Impact on DEcision Making (EVIDEM) MCDA methodology, the estimated value of nintedanib was obtained by means of an additive linear model that combined individual weights (100-points distribution) of criteria with the individual scoring of nintedanib in each criterion for every indication, assigned by a multidisciplinary committee of twelve clinicians, patients, pharmacists, and decision-makers. To assess the reproducibility, an alternative weighting method was applied, as well as a re-test of weights and scores at a different moment of time. Results The experts committee recognized nintedanib as an intervention with a positive value contribution in comparison to placebo for the treatment of non-IPF PF-ILD (0.50 ± 0.16, on a scale from -1 to 1) and SSc-ILD (0.40 ± 0.12), diseases which were considered as very severe and with high unmet needs. The drug was perceived as a treatment that provides an added therapeutic benefit for patients (0.06-0.07), given its proven clinical efficacy (0.05-0.06), slight improvements in patient-reported outcomes (0.01-0.02), and similar safety profile than placebo (-0.04-0.00), which will likely be positioned as a recommended therapy in the next clinical practice guidelines updates. Conclusions Under this increasingly used methodology, nintedanib has shown to provide a positive value estimate for non-IPF PF-ILD and SSc-ILD when compared to placebo in Spain.Universitat Autònoma de Barcelona 22022-01-0120222022-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/290599https://dx.doi.org/urn:doi:10.1017/S0266462322000459reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2905992026-06-06T12:50:31Z
dc.title.none.fl_str_mv A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases
title A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases
spellingShingle A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases
Zozaya, Néboa|||0000-0003-4618-6894
Interstitial lung diseases
Multi-criteria decision analysis
Pulmonary fibrosis
Systemic sclerosis
title_short A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases
title_full A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases
title_fullStr A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases
title_full_unstemmed A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases
title_sort A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases
dc.creator.none.fl_str_mv Zozaya, Néboa|||0000-0003-4618-6894
Arrizubieta Basterrechea, M.I.
Bollo, Elena
Castellvi, Ivan|||0000-0002-5410-5807
Espín, Jaime
Ortego, Norberto
Poveda-Andrés, José Luis
Rodríguez Portal, José Antonio
Rivero, Agustín
Marcos-Rodríguez, José Antonio
Verde, Luis
author Zozaya, Néboa|||0000-0003-4618-6894
author_facet Zozaya, Néboa|||0000-0003-4618-6894
Arrizubieta Basterrechea, M.I.
Bollo, Elena
Castellvi, Ivan|||0000-0002-5410-5807
Espín, Jaime
Ortego, Norberto
Poveda-Andrés, José Luis
Rodríguez Portal, José Antonio
Rivero, Agustín
Marcos-Rodríguez, José Antonio
Verde, Luis
author_role author
author2 Arrizubieta Basterrechea, M.I.
Bollo, Elena
Castellvi, Ivan|||0000-0002-5410-5807
Espín, Jaime
Ortego, Norberto
Poveda-Andrés, José Luis
Rodríguez Portal, José Antonio
Rivero, Agustín
Marcos-Rodríguez, José Antonio
Verde, Luis
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Interstitial lung diseases
Multi-criteria decision analysis
Pulmonary fibrosis
Systemic sclerosis
topic Interstitial lung diseases
Multi-criteria decision analysis
Pulmonary fibrosis
Systemic sclerosis
description Objectives Our aim was to assess the value of nintedanib for non-idiopathic progressive fibrosing interstitial lung disease (non-IPF PF-ILD) and systemic sclerosis-associated ILD (SSc-ILD) in the Spanish context, using a multi-criteria decision analysis (MCDA). Methods Following an adaptation of the Evidence and Value: Impact on DEcision Making (EVIDEM) MCDA methodology, the estimated value of nintedanib was obtained by means of an additive linear model that combined individual weights (100-points distribution) of criteria with the individual scoring of nintedanib in each criterion for every indication, assigned by a multidisciplinary committee of twelve clinicians, patients, pharmacists, and decision-makers. To assess the reproducibility, an alternative weighting method was applied, as well as a re-test of weights and scores at a different moment of time. Results The experts committee recognized nintedanib as an intervention with a positive value contribution in comparison to placebo for the treatment of non-IPF PF-ILD (0.50 ± 0.16, on a scale from -1 to 1) and SSc-ILD (0.40 ± 0.12), diseases which were considered as very severe and with high unmet needs. The drug was perceived as a treatment that provides an added therapeutic benefit for patients (0.06-0.07), given its proven clinical efficacy (0.05-0.06), slight improvements in patient-reported outcomes (0.01-0.02), and similar safety profile than placebo (-0.04-0.00), which will likely be positioned as a recommended therapy in the next clinical practice guidelines updates. Conclusions Under this increasingly used methodology, nintedanib has shown to provide a positive value estimate for non-IPF PF-ILD and SSc-ILD when compared to placebo in Spain.
publishDate 2022
dc.date.none.fl_str_mv 2
2022-01-01
2022
2022-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/290599
https://dx.doi.org/urn:doi:10.1017/S0266462322000459
url https://ddd.uab.cat/record/290599
https://dx.doi.org/urn:doi:10.1017/S0266462322000459
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419154178572288
score 15,300719

Similar Items